Johnson & Johnson (JNJ)vsStereotaxis Inc (STXS)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
STXS
Stereotaxis Inc
$1.87
+2.75%
HEALTHCARE · Cap: $188.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 297525% more annual revenue ($96.36B vs $32.38M). JNJ leads profitability with a 21.8% profit margin vs -66.8%. STXS appears more attractively valued with a PEG of 1.31. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
STXS
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+44.5%
Fair Value
$3.66
Current Price
$1.87
$1.79 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Revenue surging 36.3% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Trading at 13.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -143.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : STXS
The strongest argument for STXS centers on Revenue Growth. Revenue growth of 36.3% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : STXS
The primary concerns for STXS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while STXS is a hypergrowth play — different risk/reward profiles.
STXS carries more volatility with a beta of 1.42 — expect wider price swings.
STXS is growing revenue faster at 36.3% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 34/100), backed by strong 21.8% margins. STXS offers better value entry with a 44.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Stereotaxis Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (MRI) systems for use in the hospital's interventional operating room to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. The company is headquartered in St. Louis, Missouri.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?